Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
about
The emerging role of biotechnological drugs in the treatment of goutType 1 diabetesDefining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus reportMendelian Randomization and Type 2 DiabetesDisease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Evasion of inflammasome activation by microbial pathogensIL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial).A Critical Role for the Type I Interferon Receptor in Virus-Induced Autoimmune Diabetes in Rats.Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model.Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studiesMiR-30a targets IL-1α and regulates islet functions as an inflammation buffer and response factor.α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.IL-1 blockade in autoinflammatory syndromes.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.Small-molecule inhibition of inflammatory β-cell death.Modulation of virus-induced innate immunity and type 1 diabetes by IL-1 blockade.Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease.Role of genetic alterations in the NLRP3 and CARD8 genes in health and disease.Short term exposure of beta cells to low concentrations of interleukin-1β improves insulin secretion through focal adhesion and actin remodeling and regulation of gene expression.Immune therapy for treating type 1 diabetes: challenging existing paradigms.Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literatureInterleukin-12 (IL-12)/STAT4 Axis Is an Important Element for β-Cell Dysfunction Induced by Inflammatory Cytokines.Increased Blood Levels of Growth Factors, Proinflammatory Cytokines, and Th17 Cytokines in Patients with Newly Diagnosed Type 1 Diabetes.Thinking bedside at the bench: the NOD mouse model of T1DM.β-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure.Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.Innate inflammation in type 1 diabetesInvestigation of coordination and order in transcription regulation of innate and adaptive immunity genes in type 1 diabetes.Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysisImplication of the intestinal microbiome as a potential surrogate marker of immune responsiveness to experimental therapies in autoimmune diabetes.Immune interventions to preserve β cell function in type 1 diabetesHeterogeneity in recent-onset type 1 diabetes - a clinical trial perspectiveInterleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.Non-antigenic and antigenic interventions in type 1 diabetesThe role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes.Life and death of β cells in Type 1 diabetes: A comprehensive review.
P2860
Q26825459-074479C6-E892-469A-874F-2BB200966C22Q27000491-00939A71-A0CB-4A0D-AC79-05475728278DQ27687598-6EF3972B-F514-4938-8515-9EDBB401D9D7Q28072229-B24FE84F-438C-4E75-A922-4B4130CDEEC3Q28081034-664E5CFA-F48C-4FD5-9952-70749554850BQ28082757-03D2F5B0-F732-405F-B8F9-6ABF0A7884BEQ30251741-511D54F0-662F-430C-A6AA-A79827A92F95Q31132948-507CDF76-AB8C-46D2-8B85-A42E7B914510Q31812554-8235C0F4-BA39-44DC-B694-7F524217AF21Q33646749-C7126D19-A3CB-490F-A8DC-F150BAB86F86Q33661359-20019AF5-5C6E-44D1-B240-9EE505AF77BFQ33903029-71116A68-732A-4E58-A4B7-700E678E33F7Q33999020-698D938D-DF18-443F-AA61-B1AC05FAB13DQ34262561-C8471A83-99AE-458F-841E-06E9362B869CQ34375578-20B47EE8-7F35-4244-AE35-E55F2C7C883FQ34978002-618526F0-C3C3-45A0-858E-8B381212BB4CQ34996033-A413394D-F032-4C10-9280-7027AAF54FF8Q35108159-195D7EDC-3D07-4E00-BA98-FEC0198F6A6DQ35144145-CC695B2F-3207-4578-A052-FA9B0A4DA7AAQ35173044-0BC80F21-938E-41C3-BB5A-9AE52DEDF90EQ35242386-207597E6-8F0E-42B9-A482-B483B6D89D0AQ35242428-9CDB74EF-33DD-4715-B1C5-DC2A83756EC6Q35630698-E8784F89-CB3A-4038-865D-124876CA265FQ35687532-895F0B4C-CD6E-491A-8D87-582932D3E892Q35837421-4E85966B-4899-4D4A-8AD6-146B85683857Q35860851-B34B37A2-C23C-434C-86D1-567F5A018ADFQ35911875-9E0C338A-CF65-4994-A35C-B43CD60BE0E7Q36019335-134BDD4A-495D-4DE9-9D92-A4022FF64B3BQ36216535-506BBD7E-AC2D-43AF-A522-11D9EFDE34B2Q36225939-B7239266-A2BA-4055-9CC3-9BD2AD2A58E9Q36265738-DC74A339-7814-4196-9191-91CAF34715D2Q36287541-1439AF74-605C-44C3-99E0-6E7E7EC24595Q36310672-46F90307-D90C-4202-970E-CDA0BCC348C5Q36520618-82824666-E818-49CD-8805-58BC5F86EFEDQ36749719-841E7966-A868-4682-8FDC-F2012B97F333Q36788764-37DD78AD-F6C1-4041-9B1F-FDC543F6694AQ36913132-FAEC2EDC-0A48-4742-9AAE-CCD436066C63Q36977725-E94DE477-CD7F-4102-A473-53A1751AA3FBQ36995532-C2767ABB-3FC8-4B8D-8D3D-79ECE79CB052Q36995568-850182D4-843C-46D3-84E6-CEEBF05F30E6
P2860
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interleukin-1 antagonism in ty ...... ind, placebo-controlled trials
@en
Interleukin-1 antagonism in ty ...... nd, placebo-controlled trials.
@nl
type
label
Interleukin-1 antagonism in ty ...... ind, placebo-controlled trials
@en
Interleukin-1 antagonism in ty ...... nd, placebo-controlled trials.
@nl
prefLabel
Interleukin-1 antagonism in ty ...... ind, placebo-controlled trials
@en
Interleukin-1 antagonism in ty ...... nd, placebo-controlled trials.
@nl
P2093
P2860
P50
P921
P1433
P1476
Interleukin-1 antagonism in ty ...... ind, placebo-controlled trials
@en
P2093
AIDA Study Group
Ana Wägner
Anette-G Ziegler
Antoinette Moran
Bernhard Böehm
Brian Bundy
Carla J Greenbaum
Darrell M Wilson
Diane K Wherrett
Dorothy J Becker
P2860
P304
P356
10.1016/S0140-6736(13)60023-9
P407
P50
P577
2013-04-05T00:00:00Z